Last reviewed · How we verify

AK131 — Competitive Intelligence Brief

AK131 (AK131) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: CD47/SIRPα modulator. Area: Oncology.

phase 2 CD47/SIRPα modulator CD47 Oncology Small molecule Live · refreshed every 30 min

Target snapshot

AK131 (AK131) — Akeso. AK131 is a small molecule targeting the CD47/SIRPα axis to modulate the immune system.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
AK131 TARGET AK131 Akeso phase 2 CD47/SIRPα modulator CD47
Open single period A140 Open single period A140 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. phase 3 CD47 inhibitor CD47
SCTB14 SCTB14 Sinocelltech Ltd. phase 3 CD47/SIRPα axis inhibitor CD47/SIRPα axis
TBI-1301 TBI-1301 Takara Bio Inc. phase 3 CD47 antibody CD47
KI1106 4g, QD KI1106 4g, QD Kuhnil Pharmaceutical Co., Ltd. phase 3 CD47/SIRPα inhibitor CD47/SIRPα axis
Treatment Choice (TC) Treatment Choice (TC) Astex Pharmaceuticals, Inc. phase 3 SIRPα inhibitor CD47
TAK-667 TAK-667 Takeda phase 3 CD47 antibody CD47

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (CD47/SIRPα modulator class)

  1. Akeso · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AK131 — Competitive Intelligence Brief. https://druglandscape.com/ci/ak131. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: